Immix Biopharma, Inc. announced the successful completion of its 3rd engineering batch of BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 at its U.S. manufacturing site. NXC-201 will be manufactured for each individual patient using the patient?s own T cells at its cellular immunotherapy manufacturing facility in California.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.11 USD | +0.96% | -6.22% | -69.51% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-69.51% | 55.73M | |
-2.29% | 89.87B | |
-3.95% | 37.57B | |
+63.05% | 26.47B | |
-22.14% | 14.25B | |
-7.96% | 12.99B | |
-9.33% | 11.93B | |
-46.33% | 10.84B | |
+5.77% | 9.11B | |
-17.66% | 7.32B |
- Stock Market
- Equities
- IMMX Stock
- News Immix Biopharma, Inc.
- Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site